% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Mller:255485,
author = {Müller, Stephan A. and Shmueli, Merav D. and Feng, Xiao
and Tüshaus, Johanna and Schumacher, Neele and Clark, Ryan
and Smith, Brad E. and Chi, An and Rose-John, Stefan and
Kennedy, Matthew E. and Lichtenthaler, Stefan F.},
title = {{T}he {A}lzheimer’s disease-linked protease {BACE}1
modulates neuronal {IL}-6 signaling through shedding of the
receptor gp130},
journal = {Molecular neurodegeneration},
volume = {18},
number = {1},
issn = {1750-1326},
address = {London},
publisher = {Biomed Central},
reportid = {DZNE-2023-00286},
pages = {13},
year = {2023},
note = {CC BY},
abstract = {The protease BACE1 is a major drug target for Alzheimer's
disease, but chronic BACE1 inhibition is associated with
non-progressive cognitive worsening that may be caused by
modulation of unknown physiological BACE1 substrates.To
identify in vivo-relevant BACE1 substrates, we applied
pharmacoproteomics to non-human-primate cerebrospinal fluid
(CSF) after acute treatment with BACE inhibitors.Besides
SEZ6, the strongest, dose-dependent reduction was observed
for the pro-inflammatory cytokine receptor gp130/IL6ST,
which we establish as an in vivo BACE1 substrate. Gp130 was
also reduced in human CSF from a clinical trial with a BACE
inhibitor and in plasma of BACE1-deficient mice.
Mechanistically, we demonstrate that BACE1 directly cleaves
gp130, thereby attenuating membrane-bound gp130 and
increasing soluble gp130 abundance and controlling gp130
function in neuronal IL-6 signaling and neuronal survival
upon growth-factor withdrawal.BACE1 is a new modulator of
gp130 function. The BACE1-cleaved, soluble gp130 may serve
as a pharmacodynamic BACE1 activity marker to reduce the
occurrence of side effects of chronic BACE1 inhibition in
humans.},
keywords = {Mice / Humans / Animals / Alzheimer Disease: drug therapy /
Amyloid Precursor Protein Secretases / Cytokine Receptor
gp130: therapeutic use / Aspartic Acid Endopeptidases /
Interleukin-6 / Nerve Tissue Proteins / IL-6 receptor
subunit beta (Other) / IL-6R (Other) / Secretase (Other) /
Shedding (Other) / Trans-signaling (Other) / VCAM1 (Other) /
Amyloid Precursor Protein Secretases (NLM Chemicals) /
Cytokine Receptor gp130 (NLM Chemicals) / Aspartic Acid
Endopeptidases (NLM Chemicals) / Interleukin-6 (NLM
Chemicals) / BACE1 protein, human (NLM Chemicals) / Sez6
protein, mouse (NLM Chemicals) / Nerve Tissue Proteins (NLM
Chemicals) / Bace1 protein, mouse (NLM Chemicals)},
cin = {AG Lichtenthaler},
ddc = {570},
cid = {I:(DE-2719)1110006},
pnm = {352 - Disease Mechanisms (POF4-352) / DFG project 390857198
- EXC 2145: Munich Cluster for Systems Neurology (SyNergy)
(390857198)},
pid = {G:(DE-HGF)POF4-352 / G:(GEPRIS)390857198},
typ = {PUB:(DE-HGF)16},
pmc = {pmc:PMC9942414},
pubmed = {pmid:36810097},
doi = {10.1186/s13024-023-00596-6},
url = {https://pub.dzne.de/record/255485},
}